Biocon’s wholly owned subsidiary, Biocon Biologics and Evotec’s wholly owned subsidiary, Just - Evotec Biologics have entered into a strategic licensing agreement for an early-stage, pre-clinical bio-similar asset. The shares of Biocon gained nearly 2 per cent intraday on Friday.